Illumina raised its full-year 2025 adjusted per-share guidance after reporting a higher profit and revenue in the second quarter.

The maker of gene-sequencing equipment and services said Thursday it now anticipates 2025 adjusted per-share earnings between $4.45 and $4.55, an increase from the company's previously-issued guidance of between $4.20 and $4.30.

Chief Executive Jacob Thaysen said the company is helping customers navigate a constrained research funding environment.

"Even in these challenging conditions, the team's focus on operational excellence helped drive margin expansion, enabling us to increase our expectations for the year," Thaysen said.

The San Diego, Calif.-based company swung to a second-quarter profit of $235 million, or $1.49 a share, compared with a loss of $1.99 billion, or $12.48 a share, a year earlier.

Excluding one-time items, per-share earnings were $1.19, above the $1.01 per share that analysts forecast, according to FactSet.

Revenue rose to $1.06 billion from $1.11 billion a year earlier. Analysts surveyed by FactSet had expected sales of $1.01 billion.

Illumina on Thursday said it now expects total company constant currency revenue to decline between 2.5% to 0.5%, up from its previously issued guidance of 3% to 1%.

Shares of Illumina have fallen 23% this year to date. Shares were up 4% at $107 in after-hours trading on Thursday.